WO1992000740A3 - Bis-dioxopiperazines et leur utilisation en tant qu'agents protecteurs - Google Patents
Bis-dioxopiperazines et leur utilisation en tant qu'agents protecteurs Download PDFInfo
- Publication number
- WO1992000740A3 WO1992000740A3 PCT/GB1991/001156 GB9101156W WO9200740A3 WO 1992000740 A3 WO1992000740 A3 WO 1992000740A3 GB 9101156 W GB9101156 W GB 9101156W WO 9200740 A3 WO9200740 A3 WO 9200740A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- hydrogen
- maximum
- carbon atoms
- aliphatic hydrocarbon
- Prior art date
Links
- 239000011814 protection agent Substances 0.000 title 1
- 125000002015 acyclic group Chemical group 0.000 abstract 3
- 125000001931 aliphatic group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229940045200 cardioprotective agent Drugs 0.000 abstract 1
- 239000012659 cardioprotective agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Chemical group C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 abstract 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- -1 trimethylene, tetramethylene Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Composés de la formule (II), où n vaut 0, 1 ou 2, R1, R2, R3 et R4 sont chacun indépendamment choisis à partir d'hydrogène, de groupes hydrocarbures aliphatiques acycliques non substitués comportant un maximum de six atomes de carbone et de groupes alkyle C1-6 substitués par un groupe hydroxyle ou par un groupe alcoxy C1-6, ou l'un d'entre R1 et R2 et l'un d'entre R3 et R4 représente hydrogène et les autres forment ensemble un groupe de liaison de triméthylène, tétraméthylène ou pentaméthylène, R5 représente hydrogène ou un groupe hydrocarbure aliphatique acyclique non substitué comportant un maximum de six atomes de carbone, et R6 représente un groupe hydrocarbure aliphatique acyclique comportant un maximum de six atomes de carbone ou un groupe CH2R7 dans lequel R7 représente un groupe alkyle C1-5 substitué par un groupe hydroxyle ou par un groupe alcoxy C1-6, ou un sel de ceux-ci préparé avec un acide organique ou inorganique pharmaceutiquement acceptable. Ces composés sont utiles en thérapie, en particulier comme agents cardio-protecteurs.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9015435.2 | 1990-07-13 | ||
| GB909015435A GB9015435D0 (en) | 1990-07-13 | 1990-07-13 | Pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1992000740A2 WO1992000740A2 (fr) | 1992-01-23 |
| WO1992000740A3 true WO1992000740A3 (fr) | 1992-03-19 |
Family
ID=10679046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB1991/001156 WO1992000740A2 (fr) | 1990-07-13 | 1991-07-12 | Bis-dioxopiperazines et leur utilisation en tant qu'agents protecteurs |
Country Status (2)
| Country | Link |
|---|---|
| GB (2) | GB9015435D0 (fr) |
| WO (1) | WO1992000740A2 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9115596D0 (en) * | 1991-07-12 | 1991-09-04 | Creighton Andrew M | Pharmaceutical compositions |
| CZ309069B6 (cs) | 2020-01-16 | 2022-01-12 | Univerzita Karlova V Praze | Použití derivátů sloučeniny ICRF-193 a farmaceutický přípravek k prevenci chronické kumulativní kardiotoxicity způsobené terapií antracyklinovými protinádorovými léčivy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1240700B (de) * | 1960-10-31 | 1967-05-18 | Eastman Kodak Co | Duesentreibstoffe |
| NL273690A (fr) * | 1961-01-19 | 1900-01-01 | ||
| GB8916072D0 (en) * | 1989-07-13 | 1989-08-31 | Creighton Andrew M | Pharmaceutical compositions |
-
1990
- 1990-07-13 GB GB909015435A patent/GB9015435D0/en active Pending
-
1991
- 1991-07-12 WO PCT/GB1991/001156 patent/WO1992000740A2/fr active Application Filing
- 1991-07-12 GB GB9115156A patent/GB2245832A/en not_active Withdrawn
Non-Patent Citations (6)
| Title |
|---|
| Advances in Pharmacology and Chemotherapy, volume 19, 1982, Academic Press, Inc.; E.H. Herman et al.: "Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds", pages 249-290, see pages 255-256,263,278-286 (cited in the application) * |
| Cancer Chemother. Pharmacol., volume 16, 1986, Springer-Verlag; R.H. Herman et al.: "Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits", pages 102-106, see the whole article * |
| Cancer Chemother. Pharmacol., volume 19, 1987, Springer-Verlag; E.H. Herman et al.: "Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159)", pages 277-281, see the whole article * |
| Int. J. Clin. Pharm. Res., volume VI, no. 2, 1986, S.A. Mortensen et al.: "Clinical and non-invasive assessment of anthracycline cardiotoxicity: perspctives on myocardial protection", pages 137-150, see the whole article * |
| New Eng. J. Med., volume 319, no. 12, 1988, J.L. Speyer et al.: "Protective effects of the bispiperazinedone ICR5-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer", pages 745-752, see the whole article * |
| Research Communications in Chemical Pathology and Pharmacology, volume 48, no. 1, April 1985, E.H. Herman et al.: "Comparison of the protective effect of ICRF-187 and structurally related analogues against acute daunorubicin toxicity in syrian golden hamsters", pages 39-55, see abstract; figure 1; table 1 (cited in the application) * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB9015435D0 (en) | 1990-08-29 |
| GB9115156D0 (en) | 1991-08-28 |
| WO1992000740A2 (fr) | 1992-01-23 |
| GB2245832A (en) | 1992-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO302755B1 (no) | Morfinan-derivater | |
| HU9203304D0 (en) | 3-benzylidene-1-carbamoyl-2-pyrrolidone analogues | |
| EP0976732A4 (fr) | Derives amines cycliques 1,4-substitues | |
| ES2076471T3 (es) | Compuestos anionicos. | |
| EP0775487A4 (fr) | Derive de triazine et medicament | |
| EP1029860A4 (fr) | Derives de benzofuranne | |
| AU1739092A (en) | 1-methylcarbapenem derivatives, their preparation and their use as antibiotics | |
| HUT73437A (en) | Novel pyrrolocarbazoles | |
| IL94027A0 (en) | Diaminoethylene compounds | |
| DE69127691D1 (de) | Be-13793c-derivat mit antitumorwirkung | |
| ES2093091T3 (es) | Derivado de glutation. | |
| WO1991000729A3 (fr) | Bis-dioxopiperazines, et leur utilisation en tant qu'agents de protection | |
| MY131762A (en) | Pharmaceutical compounds | |
| NO921159D0 (no) | Tiazolidinon- og oksazolidinonderivater, fremgangsmaate til fremstilling derav, samt anvendelse av derivatene som vasodilatorer | |
| AU626095B2 (en) | Hydroxyalkane carboxylic acid derivatives, their production and use | |
| MX170732B (es) | Composicion de derivados de succinimida y su uso | |
| MX9101270A (es) | Compuesto,preparacion y uso | |
| EP0601191A4 (en) | Novel tetracyclic compound. | |
| WO1992000740A3 (fr) | Bis-dioxopiperazines et leur utilisation en tant qu'agents protecteurs | |
| HK1032916A1 (en) | N,n'-bis(sulfonyl)hydrazines useful as antineoplastic agents | |
| ATE105565T1 (de) | Pradimicinderivate. | |
| DK0538517T3 (da) | Nye organo-tinforbindelser med antitumoraktivitet og antitumormidler | |
| ATE284402T1 (de) | Pyrroloindol-derivate und zwischenprodukte zu ihrer herstellung | |
| TWI256383B (en) | Anthraquinone compound | |
| JPS55104266A (en) | Novel pyridone derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
| 122 | Ep: pct application non-entry in european phase |